Reasons for prescribing cognition enhancers in primary care. Results of a representative survey in Lower Saxony, Germany.
With regard either to the controversial debate about the efficacy of cognition enhancers (CEs) or to the high costs which the frequent prescription of these drugs causes the German health system's economy, we wanted to know what physicians expect from a therapy with these drugs.
We performed a representative survey (response rate 83.2%) in Lower Saxony, Germany from February to July 1993.
We designed two written case vignettes which described either a patient with slight memory problems or a moderately demented patient who also suffers from common systemic disorders.
In a face-to-face interview 145 general practitioners and primary care internists (family physicians) and 14 community neuropsychiatrists answered the question, whether they would prescribe CEs to each of the patients described and what they would expect from this therapy. 70.4% of all physicians would prescribe a cognition enhancer to the slightly impaired patient and 63.5% to the multimorbid moderately demented patient, respectively.
More than 50% of the family physicians would not expect any positive therapeutic effect in both patients, while the neuropsychiatrists did so in 57.1% in the patient with slight memory disturbances and in 35.7% in the moderately demented patient.
In conclusion, the results of this study clearly demonstrate that cognition enhancers are prescribed in spite of major doubts in their efficacy.
Mots-clés Pascal : Nootrope, Psychotrope, Prescription médicale, Médecin, Efficacité traitement, Allemagne, Europe, Economie santé
Mots-clés Pascal anglais : Nootropic agent, Psychotropic, Medical prescription, Physician, Treatment efficiency, Germany, Europe, Health economy
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0489582
Code Inist : 002B02B02. Création : 01/03/1996.